文献速递临床免疫质量管理与危急值

自动化电化学发光免疫法测定全血西罗莫司浓度的多中心评价

Measurement of sirolimus concentrations in human blood using an automated electrochemiluminescence immunoassay (ECLIA): a multicenter evaluation.
PubMed 文献 · Clin Chem Lab Med · 2018-01-01

该研究在五家欧洲实验室评估了新型电化学发光免疫法(ECLIA)测定全血西罗莫司浓度的性能,包括重复性、中间精密度和功能灵敏度,并与液相色谱-串联质谱(LC-MS/MS)及两种免疫法进行方法学比较,所用样本来自肾移植患者。结果显示ECLIA精密度良好、功能灵敏度优异,与LC-MS/MS及其他免疫法相关性好,提示其适用于移植受者治疗药物监测,可作为LC-MS/MS的替代方法。

要点

  • ECLIA测定西罗莫司的重复性CV≤6.4%,中间精密度CV≤10.7%。
  • ECLIA功能灵敏度优异,在定量下限1.5 μg/L处CV为7.0%。
  • ECLIA与LC-MS/MS及CMIA、ACMIA相关性良好,适用于临床TDM。

核心结论

  • ECLIA测定全血西罗莫司精密度、功能灵敏度良好,与LC-MS/MS及其他免疫法一致性佳,适用于移植受者TDM并可替代LC-MS/MS。

研究设计与样本

  • 在五家欧洲实验室评估新型ECLIA测定全血西罗莫司的性能,包括重复性、中间精密度和功能灵敏度实验,并与LC-MS/MS及两种免疫法(CMIA、ACMIA)进行方法学比较,所用样本为肾移植患者天然样本。

主要发现

  • 重复性和中间精密度CV分别≤6.4%和≤10.7%(覆盖西罗莫司浓度范围)。
  • 功能灵敏度优异:CV未达到20%,在定量下限1.5 μg/L处CV为7.0%。
  • 与LC-MS/MS比较:加权Deming回归斜率1.05、截距0.154 μg/L、Pearson相关系数r=0.94;Bland-Altman分析合并平均偏倚0.41 μg/L(±2SD,-1.96至2.68)。
  • 与CMIA比较:斜率0.91、截距0.112 μg/L、r=0.89;与ACMIA比较:斜率0.99、截距0.319 μg/L、r=0.97。

临床怎么用

  • ECLIA可用于移植受者西罗莫司治疗药物监测,为临床提供LC-MS/MS之外的替代选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Therapeutic drug monitoring (TDM) of sirolimus is essential in transplant recipients. We evaluated the performance of a new electrochemiluminescence immunoassay (ECLIA) for measuring sirolimus concentrations in whole blood at five European laboratories. METHODS: Study assessments included repeatability, intermediate precision and functional sensitivity (concentration at coefficient of variation [CV] of 20%) experiments. Method comparisons with liquid chromatography-tandem mass spectrometry (LC-MS/MS; reference method) and two immunoassays (chemiluminescent microparticle immunoassay [CMIA] and antibody-conjugated magnetic immunoassay [ACMIA]) were performed using native samples from patients with kidney transplants. RESULTS: Imprecision testing CVs were ≤6.4% and ≤10.7% across the sirolimus concentration range for both repeatability and intermediate precision, respectively. The ECLIA showed excellent functional sensitivity: the CV did not reach 20%; the CV at the assay's limit of quantitation (1.5 μg/L) was 7.0%. Agreement between the ECLIA and LC-MS/MS using native kidney samples was close, with weighted Deming regression analysis yielding a slope of 1.05, an intercept of 0.154 μg/L and a Pearson's correlation coefficient (r) of 0.94, while Bland-Altman analysis showed a combined mean bias of 0.41 μg/L (±2 standard deviation [SD], -1.96 to 2.68). The ECLIA also showed good correlation with the two other immunoassays: the CMIA (slope=0.91, intercept=0.112 μg/L and r=0.89) and the ACMIA (slope=0.99, intercept=0.319 μg/L and r=0.97). CONCLUSIONS: The ECLIA showed good precision, functional sensitivity and agreement with other methods of sirolimus measurement used in clinical practice, suggesting that the assay is suitable for TDM in transplant recipients and provides an alternative to LC-MS/MS.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Stove V, Ramos PA, Wallemacq P, et al. Measurement of sirolimus concentrations in human blood using an automated electrochemiluminescence immunoassay (ECLIA): a multicenter evaluation. Clin Chem Lab Med. 2018. PMID: 29206642. doi:10.1515/cclm-2017-0583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。